Moderna

Despite the development of three new RSV vaccines for adults 60 and older, vaccine uptake remains low due to COVID- and flu-induced vaccine fatigue and lack of awareness. The FDA approved the first RSV vaccine in 2023, with Moderna, Pfizer, and GSK following suit in 2024. However, only 25% of eligible adults had received the vaccine by spring 2024, and a survey showed that 38% of eligible recipients plan to get the vaccine, citing concerns about side effects and general distrust. The CDC recommends the vaccine for those 75 and older and those 60-74 with chronic conditions or living in nursing homes.

RSV is a contagious virus affecting lungs, nose, and throat, with severe impacts on infants and older adults. Preventive options include maternal RSV vaccine (Abrysvo) and monoclonal antibody injection (Beyfortus) for infants, and three vaccines for adults 60+ (Arexvy, Abrysvo, mResvia). Uptake remains low despite WHO recommendations.

Moderna has dosed the first participant in its Phase 3 trial for mRNA-1403, an investigational norovirus vaccine. Norovirus, a contagious gastrointestinal virus, spreads through direct contact, contaminated food, and surfaces. The trial aims to enroll 25,000 participants globally to assess mRNA-1403's efficacy, safety, and immunogenicity, focusing on adults, particularly those 60 and older. Prevention measures include handwashing, thorough cooking, and surface disinfection.

mRNA cancer vaccines in clinical trials: >60 vaccines, highest phase III (2 vaccines), US and China dominate with >45 vaccines, skin cancer trials leading with >10 vaccines. First commercial approval expected by 2029. mRNA vaccines promise targeted, personalized cancer therapies, overcoming conventional limitations.

mRNA cancer vaccines in clinical trials exceed 60, with 2 in Phase III. Expected commercial approval by 2029. US and China lead in trials, with skin cancer dominating. mRNA vaccines promise targeted, personalized cancer treatments.

Moderna's Nova 301 trial, a phase 3 study evaluating mRNA-1403, an investigational norovirus vaccine, has dosed its first US participant. The trial aims to enroll 25,000 participants globally to assess efficacy, safety, and immunogenicity, focusing on older adults at risk of severe norovirus outcomes.

The article discusses the importance of summarizing content accurately and concisely, focusing on retaining original expressions while ensuring clarity.

Resolution Therapeutics secures $85 million in series B financing to advance RTX001, a pro-regenerative macrophage therapy for end-stage liver disease, into clinical trials. RTX001 aims to address severe inflammation and fibrosis, with a phase 1/2 EMERALD trial set to begin in Q4 2024. The financing also supports pipeline growth and manufacturing enhancements.

Pharma companies like Novo Nordisk, Viking Therapeutics, Amgen, and CRISPR Therapeutics are set to announce clinical trial results for next-gen weight loss drugs and a cancer/autoimmune disease cell therapy. Moderna may also launch a new product beyond its COVID-19 vaccine.